CD274 and neoplasm: It’s worth noting that blocking the adenosine/adenosine receptor pathway combined with immune checkpoint inhibitors such as anti-PD-1 or anti-CTLA-4 can significantly enhance the efficacy of anti-PD-1 or anti-CTLA-4, including in anti-PD-1-/anti-PD-L1-tolerant tumor types.